The AACR editors are proud to present this selection of impactful journal articles focusing on immunoncology and immunotherapy, published from across the AACR journal portfolio.
- Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer.
Anagnostou V Velculescu V. Cancer Discovery March 2017.
- Primary resistance to PD-1 blockade mediated by JAK1/2 mutations.
Shin D Ribas A. Cancer Discovery February 2017.
- Targeted next generation sequencing identifies markers of response to PD-1 blockade.
Johnson DB Lovly CM. Cancer Immunology Research November 2016.
- Temporally-distinct PD-L1 expression by tumor and host cells contributes to immune escape.
Takuro N Schreiber RD. Cancer Immunology Research February 2017.
- VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma.
Wu X Hodi FS. Cancer Immunology Research October 2016.
- Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy.
Page DB McArthur HL. Cancer Immunology Research October 2016.
- Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy.
Ahmad S Khleif SN. Cancer Research January 2017.
- Intrinsic resistance of solid tumors to immune checkpoint blockade therapy.
Zhao X Subramanian S. Cancer Research February 2017.
- In vivo fluorescence imaging of the activity of CEA TCB, a novel T-cell bispecific antibody, reveals highly specific tumor targeting and fast induction of T-cell-mediated tumor killing.
Lehmann S Bacac M. Clinical Cancer Research September 2016.
- Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.
Weide B Wolchok JD. Clinical Cancer Research November 2016.
- Phosphatidylserine sensing by TAM receptors regulates AKT-dependent chemoresistance and PD-L1 expression.
Kasikara C Birge R. Molecular Cancer Research January 2017.
- Inflammatory molecule, PSGL-1, deficiency activates macrophages to promote colorectal cancer growth through NF-kappaB signaling.
Li J Wang L. Molecular Cancer Research January 2017.
- Clinical dosing regimen of selinexor maintains normal immune homeostasis and T cell effector function in mice: implications for combination with immunotherapy.
Tyler PM Dougan SK. Molecular Cancer Therapeutics February 2017.